Gore Global Registry for Endovascular Aortic Treatment Reaches 2,500 Enrolled Patients
Milestone Achievement in Monitoring Patient Outcomes and Device Performance
First Patient Enrolled in GORE® TAG® Thoracic Branch Endoprosthesis Early Feasibility Study
First Early Feasibility Study of a Gore Device Will Assess Treatment of Aortic Arch Aneurysms
GORE® EXCLUDER® Conformable AAA Endoprosthesis Receives Approval for Clinical Study in the US and Japan
Device designed to bring endovascular therapy options to patients previously considered untreatable
GORE® DrySeal Flex Introducer Sheath Advances Care through Access
New sheath provides exceptional access to challenging anatomies and branch vessels
GORE® EXCLUDER® AAA Endoprosthesis Gore Completes Primary Enrollment for the Gore EXCLUDER® Iliac Branch Clinical Study
62 patients enrolled in US investigational device exemption clinical study to assess first complete, low-profile system for managing common iliac artery aneurysms or aorto-iliac aneurysms
Gore Completes Patient Enrollment in U.S. Pivotal Clinical Study of GORE® CARDIOFORM ASD Occluder
New addition to GORE® CARDIOFORM Occluder family is designed to treat larger atrial septal defects by adapting to the patient’s anatomy for a permanent and safe closure
Celebrating the 20th Anniversary of the GORE® EXCLUDER® Device
With two decades of evolution and more than 300,000 patients treated* worldwide, this trusted, market-leading EVAR device continues to advance patient care
Gore Launches Anti-Migration Assurance Program for GORE® VIABIL® Short Wire Biliary Endoprosthesis
Device is proven to reduce the risk of reintervention for patients with pancreatic and other cancers that obstruct the bile duct; replacement program can help limit overall costs of palliative care